317 related articles for article (PubMed ID: 25918904)
1. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
[TBL] [Abstract][Full Text] [Related]
2. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
[TBL] [Abstract][Full Text] [Related]
3. Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study.
Orii Y; Kunikane E; Yamada Y; Morioka M; Iwasaki K; Arimura S; Mizuno A; Inatani M
PLoS One; 2022; 17(12):e0277313. PubMed ID: 36454807
[TBL] [Abstract][Full Text] [Related]
4. Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations.
Suzuki G; Kunikane E; Shigemi W; Shinno K; Kozai S; Kurata M; Kawamura A
Curr Eye Res; 2021 Mar; 46(3):380-386. PubMed ID: 32706598
[TBL] [Abstract][Full Text] [Related]
5. Vitreous concentration of topically applied brimonidine tartrate 0.2%.
Kent AR; Nussdorf JD; David R; Tyson F; Small D; Fellows D
Ophthalmology; 2001 Apr; 108(4):784-7. PubMed ID: 11297498
[TBL] [Abstract][Full Text] [Related]
6. Vitreous concentration of topically applied brimonidine-purite 0.15%.
Kent AR; King L; Bartholomew LR
J Ocul Pharmacol Ther; 2006 Aug; 22(4):242-6. PubMed ID: 16910864
[TBL] [Abstract][Full Text] [Related]
7. Ocular Distribution of Brimonidine and Brinzolamide after Topical Instillation of a 0.1% Brimonidine Tartrate and 1% Brinzolamide Fixed-Combination Ophthalmic Suspension: An Interventional Study.
Orii Y; Kunikane E; Yamada Y; Morioka M; Iwasaki K; Arimura S; Mizuno A; Inatani M
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445209
[TBL] [Abstract][Full Text] [Related]
8. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%.
Schoenberger SD; Kim SJ; Sheng J; Calcutt MW
JAMA Ophthalmol; 2014 Feb; 132(2):150-4. PubMed ID: 24264034
[TBL] [Abstract][Full Text] [Related]
9. Penetration of ofloxacin in human aqueous and vitreous humors following oral and topical administration.
Cekic O; Batman C; Yasar U; Basci NE; Bozkurt A; Kayaalp SO
Retina; 1998; 18(6):521-5. PubMed ID: 9869460
[TBL] [Abstract][Full Text] [Related]
10. Effect of Brimonidine on the B Cells, T Cells, and Cytokines of the Ocular Surface and Aqueous Humor in Rat Eyes.
Shin HY; Lee HS; Lee YC; Kim SY
J Ocul Pharmacol Ther; 2015 Dec; 31(10):623-6. PubMed ID: 26401980
[TBL] [Abstract][Full Text] [Related]
11. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.
Hariprasad SM; Blinder KJ; Shah GK; Apte RS; Rosenblatt B; Holekamp NM; Thomas MA; Mieler WF; Chi J; Prince RA
Arch Ophthalmol; 2005 Jan; 123(1):39-44. PubMed ID: 15642810
[TBL] [Abstract][Full Text] [Related]
12. Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown.
Shen J; Durairaj C; Lin T; Liu Y; Burke J
Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1056-66. PubMed ID: 24448267
[TBL] [Abstract][Full Text] [Related]
13. Absorption of brimonidine 0.1% and 0.15% ophthalmic solutions in the aqueous humor of cataract patients.
Cantor LB; WuDunn D; Catoira-Boyle Y; Yung CW
J Glaucoma; 2008; 17(7):529-34. PubMed ID: 18854728
[TBL] [Abstract][Full Text] [Related]
14. Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration.
Cekiç O; Batman C; Yasar U; Başci NE; Bozkurt A; Kayaalp SO
Eye (Lond); 1999 Aug; 13 ( Pt 4)():555-8. PubMed ID: 10692930
[TBL] [Abstract][Full Text] [Related]
15. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans.
Vemulakonda GA; Hariprasad SM; Mieler WF; Prince RA; Shah GK; Van Gelder RN
Arch Ophthalmol; 2008 Jan; 126(1):18-22. PubMed ID: 18195213
[TBL] [Abstract][Full Text] [Related]
16. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes.
Acheampong AA; Shackleton M; John B; Burke J; Wheeler L; Tang-Liu D
Drug Metab Dispos; 2002 Apr; 30(4):421-9. PubMed ID: 11901096
[TBL] [Abstract][Full Text] [Related]
17. Ocular pharmacokinetics profile of different indomethacin topical formulations.
Bucolo C; Melilli B; Piazza C; Zurria M; Drago F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
[TBL] [Abstract][Full Text] [Related]
18. Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug.
Park CG; Kim YK; Kim MJ; Park M; Kim MH; Lee SH; Choi SY; Lee WS; Chung YJ; Jung YE; Park KH; Choy YB
J Control Release; 2015 Dec; 220(Pt A):180-188. PubMed ID: 26478018
[TBL] [Abstract][Full Text] [Related]
19. α2-Adrenergic modulation of the glutamate receptor and transporter function in a chronic ocular hypertension model.
Jung KI; Kim JH; Park CK
Eur J Pharmacol; 2015 Oct; 765():274-83. PubMed ID: 26300392
[TBL] [Abstract][Full Text] [Related]
20. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits.
Dong JQ; Babusis DM; Welty DF; Acheampong AA; Tang-Liu D; Whitcup SM
J Ocul Pharmacol Ther; 2004 Aug; 20(4):285-92. PubMed ID: 15321023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]